Ovarian Cancer Market Size, Share, Industry, Forecast and Outlook (2026-2033)

Ovarian Cancer Market Size

Global Ovarian Cancer Market reached US$ 3.42 billion in 2025 and is expected to reach US$ 18.6 billion by 2033, growing with a CAGR of 23.7% during the forecast period 2026-2033.

Ovarian cancer is a deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.

The main treatments for ovarian cancer are Surgery and chemotherapy. The treatment depends on several factors, including cancer stage and grade. Ovarian cancer can only be definitively diagnosed through a surgical biopsy. Surgical debulking, radiotherapy, and chemotherapy remain the mainstream treatment modalities.

Furthermore, monoclonal antibodies are considered both immunotherapy agents and targeted therapies for ovarian cancer. Checkpoint inhibitors are also used in the treatment. Rising advancements in cancer research, the increasing prevalence of ovarian cancer among females, and increasing clinical trials are a few factors that drive the market in the forthcoming period.

Ovarian Cancer Market Scope

       For More Details on This Report: Request for Sample

Market Disruption

The ovarian cancer market is undergoing a structural shift driven by precision oncology and biologics-led innovation. Traditional chemotherapy-based treatment paradigms are being steadily replaced by targeted therapies such as PARP inhibitors, antibody-drug conjugates, and immunotherapies. A key disruption lies in the rapid emergence of biomarker-driven treatments targeting BRCA mutations, FRα expression, and KRAS pathways, enabling highly personalized treatment strategies. Additionally, ADCs are redefining therapeutic efficacy by combining targeted delivery with cytotoxic payloads, improving outcomes in platinum-resistant cases. Regulatory acceleration mechanisms such as breakthrough therapy designations are shortening time-to-market for innovative drugs. Another major shift is the integration of AI and real-world data in clinical trial design, improving patient stratification and success rates. The convergence of diagnostics and therapeutics is transforming the market into a precision-driven ecosystem focused on improved survival and reduced relapse rates.

Ovarian Cancer Market Dynamics

Increasing Endometriosis Cases among Females 

Endometriosis increases the risk of developing epithelial ovarian cancer (EOC). Younger women diagnosed with endometriosis were at increased risk of developing endometriosis-associated ovarian carcinoma (EOAC). Females with an endometriosis history are more prone to ovarian cancer, as delayed diagnosis of endometriosis can directly lead to tumor formation, which leads to severe implications. 

According to the World Health Organisation's March 2023 issue, endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally. There is currently no known cure for endometriosis, and treatment is usually aimed at controlling symptoms.

Access to early diagnosis and effective endometriosis treatment is essential but limited in many settings, including in low- and middle-income countries. Ovarian cancer remains the deadliest type of gynecological cancer in women. Nearly 1 in 76 women are at risk of developing ovarian cancer in their lifetime; endometriosis increases this slightly to 1 in 5.

Rising Pipeline Drugs

The US FDA recently granted accelerated approval to our lead product for treating ovarian cancer, and we have several novel ADCs in development in our pipeline. Major drug developers are investigating their lead agents in combination therapies to gradually progress into the front line of ovarian cancer treatment to replace chemotherapies soon.

MIRASOL, Monotherapy in FRα-High Platinum-Resistant Ovarian Cancer (Randomized Confirmatory Trial) positive top-line data reported MAY 2023. Genentech’s Avastin (bevacizumab) and poly ADP-ribose polymerase (PARP) inhibitors. AstraZeneca’s Lynparza (olaparib), Tesaro’s Zejula (niraparib), and Clovis Oncology’s Rubraca (rucaparib) are paving the way for more targeted therapies and novel agents with new mechanisms of action (MOAs). GLORIOSA, doublet with Mirvetuximab & Bevacizumab Maintenance in FRα-High Platinum-Sensitive Ovarian Cancer. 

Drug Resistance

Drug Resistance for ovarian cancer treatment is increasing because of the tumor cell resistance to the chemotherapeutic drugs in some or other pathways. The traditional treatment for ovarian cancer is platinum-based chemotherapy (carboplatin or cisplatin) in combination with paclitaxel, and it has remained the same for the past two decades. Most patients are initially responsive to these treatments; however, relapse occurs in around 80% of women due to platinum resistance. One of the metabolic pathways is a crucial driver of metastasis and drug resistance in many different cancers, including ovarian cancer. Discoveries in novel resistance mechanisms and approaches to overcome drug resistance through nanomedicine shortly.

Ovarian Cancer Market Segment Analysis

The global is segmented based on type, treatment type, end user, and region.

The Chemotherapy Segment Accounted for Approximately 54.3% of the Market Share by 2025

Epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are phase III randomized study evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, 

A phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early degeneration (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more.

Ovarian Cancer Market Geographical Share

North America accounted for Approximately 39.1% of the Market Share in 2025

North America is predicted to command the global ovarian cancer market since North America has the highest prevalence of ovarian cancer and the largest portion of the global population. For instance, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 78. Her lifetime chance of dying from ovarian cancer is about 1 in 108. The American Cancer Society estimates for ovarian cancer in the United States for 2023 over 20,000 women will receive a new diagnosis of ovarian cancer, and about 13,270 women will die from ovarian cancer.

Clinical trials are essential to improving cancer treatment, especially in highly lethal cancers like ovarian cancer. Major cancer organizations, including the National Comprehensive Cancer Network, American Society of Clinical Oncology, and Association of Community Cancer Centers, endorse that all cancer patients should consider and have the opportunity to participate in clinical trials. Black or African American patients comprised 8% of participants in clinical trials despite making up 14% of the US population. Similarly, Hispanics comprised 11% of participants in clinical trials but 18% of the US population. 

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global ovarian cancer market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.

The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of cancer-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market. 

Key Developments

• In April 2026, GlaxoSmithKline announced positive Phase I results for its B7-H4–targeted antibody-drug conjugate (mocertatug rezetecan), demonstrating around 62% response rates in platinum-resistant ovarian cancer, with plans to advance into Phase III trials.
• In October 2025, AstraZeneca presented strong clinical data for its FRα-targeting ADC (Torvutamab), achieving response rates of up to ~61% in platinum-resistant ovarian cancer, highlighting progress in targeted biologics.
• In September 2025, Merck & Co., in collaboration with Daiichi Sankyo, received FDA Breakthrough Therapy Designation for raludotatug deruxtecan (CDH6-targeting ADC), accelerating development for ovarian cancer treatment.
• In May 2025, Bristol-Myers Squibb supported the approval ecosystem for the combination therapy avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer, marking a key milestone in targeted therapy.
• In 2025, leading companies such as Roche, Novartis, and Pfizer expanded their oncology pipelines through collaborations and advancements in antibody-drug conjugates and immunotherapies.

Ovarian Cancer Market Key Players

The major global players in the ovarian cancer market include AstraZeneca, Roche, GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck among others.

Company Profile

AstraZeneca

AstraZeneca is a leading player in the ovarian cancer market with a strong focus on precision oncology. Its flagship product, Lynparza (developed in partnership with Merck), is a widely used PARP inhibitor for ovarian cancer treatment, particularly in patients with BRCA mutations. The company continues to strengthen its oncology pipeline through advancements in antibody-drug conjugates, including its FRα-targeting candidate Torvutamab, which has shown promising clinical outcomes in resistant cases. AstraZeneca is also investing heavily in artificial intelligence and biomarker-driven research to enhance drug discovery and patient selection, positioning itself at the forefront of next-generation targeted therapies.

GlaxoSmithKline

GlaxoSmithKline (GSK) has established a solid presence in the ovarian cancer segment through its PARP inhibitor Zejula, which it gained via the acquisition of Tesaro. The company is now expanding beyond traditional therapies into advanced biologics, particularly antibody-drug conjugates such as mocertatug rezetecan, which has demonstrated strong clinical efficacy in early trials. GSK’s oncology strategy is centered on developing highly targeted therapies and improving outcomes in hard-to-treat cancers. With continuous investment in immuno-oncology and next-generation therapeutics, GSK is actively reshaping its oncology portfolio to address unmet medical needs in ovarian cancer.

Roche

Roche plays a significant role in the ovarian cancer market with its well-established drug Avastin, which is commonly used in combination therapies. The company focuses on personalized healthcare by integrating diagnostics with therapeutics, enabling more precise treatment approaches. Roche is actively advancing its pipeline in antibody-drug conjugates and immunotherapy, aiming to improve survival outcomes in ovarian cancer patients. Its innovation strategy emphasizes combination therapies and biomarker-driven treatments, supported by strong R&D capabilities and a commitment to precision medicine.

Bristol-Myers Squibb

Bristol-Myers Squibb is a key contributor to the oncology landscape, with a strong emphasis on immunotherapy and combination treatment strategies. While widely known for its checkpoint inhibitor Opdivo, the company is also involved in advancing targeted therapies for ovarian cancer through collaborations and pipeline developments. Its role in enabling new treatment combinations, such as KRAS-targeted therapies, reflects its commitment to expanding therapeutic options in difficult-to-treat cancers. BMS continues to invest in innovative research focused on immune modulation and precision oncology, strengthening its long-term position in the ovarian cancer market.

Why Purchase the Report?

• To visualize the global ovarian cancer market segmentation based on type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ovarian cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global ovarian cancer market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies